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Abstract
Background: The identification of a blood-based diagnostic marker is a goal in many areas of medicine, including the early
diagnosis of prostate cancer. We describe the use of averaged differential display as an efficient mechanism for biomarker
discovery in whole blood RNA. The process of averaging reduces the problem of clinical heterogeneity while simultaneously
minimizing sample handling.
Methodology/Principal Findings: RNA was isolated from the blood of prostate cancer patients and healthy controls.
Samples were pooled and subjected to the averaged differential display process. Transcripts present at different levels
between patients and controls were purified and sequenced for identification. Transcript levels in the blood of prostate
cancer patients and controls were verified by quantitative RT-PCR. Means were compared using a t-test and a receiver-
operating curve was generated. The Ring finger protein 19A (RNF19A) transcript was identified as having higher levels in
prostate cancer patients compared to healthy men through the averaged differential display process. Quantitative RT-PCR
analysis confirmed a more than 2-fold higher level of RNF19A mRNA levels in the blood of patients with prostate cancer
than in healthy controls (p=0.0066). The accuracy of distinguishing cancer patients from healthy men using RNF19A mRNA
levels in blood as determined by the area under the receiving operator curve was 0.727.
Conclusions/Significance: Averaged differential display offers a simplified approach for the comprehensive screening of
body fluids, such as blood, to identify biomarkers in patients with prostate cancer. Furthermore, this proof-of-concept study
warrants further analysis of RNF19A as a clinically relevant biomarker for prostate cancer detection.
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Introduction
While metastatic prostate cancer remains an incurable disease
[1], intervention when the disease is still localized, and usually
asymptomatic, is often curative [2,3,4]. Since early intervention is
known to reduce mortality in men with prostate cancer [5], early
detection holds the promise of reducing prostate cancer-specific
mortality rates but its effectiveness has yet to be established.
Prostate-specific antigen (PSA) is the only biomarker commonly in
use for this purpose but has limitations with imperfect specificity
and sensitivity. A normal PSA does not exclude the presence of
potentially lethal prostate cancer [6] while benign prostatic disease
can cause elevations in PSA that may require prostate biopsy for
diagnosis. The limitations of PSA screening in reducing prostate-
cancer mortality were seen clearly when two large randomized
controlled trials published conflicting results [7,8]. Even if
interpreted in a favorable light, the results suggested that survival
benefit from PSA screening was small, with 50 men needing to
undergo prostatectomy to save one life [7]. This result also
highlights the problem of prostate cancer overdiagnosis, when
many men are diagnosed with an indolent prostate cancer that will
not impact their mortality even if left untreated. However, the fact
that prostate cancer remains the second-leading cause of cancer-
related death in men [9] is a reminder of the importance of
detecting potentially lethal prostate cancer when it is still curable.
Thus, the identification of additional biomarkers to improve on
the performance of PSA remains an important goal in prostate
cancer early detection, especially in the detection of aggressive
disease.
We describe here the usefulness of an averaged differential
expression (ADE) approach to identify biomarkers in blood
samples of men with prostate cancer. Differential display
methodology does not require prior knowledge of RNA tran-
scripts. Differential display thus offers an ‘‘open’’ system in which
both known and unknown RNA transcripts associated with a
disease state can be identified, a fact that distinguishes it from
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amounts of starting RNA (as little as 20 ng total RNA), and offers
an unparalleled potential for rapid identification of RNA
transcripts present at different levels in test versus reference
samples; it is especially efficient at identifying low abundance
transcripts [11] that cannot be detected by hybridization-based
microarray screening technologies. Differential display also offers
an excellent opportunity to interrogate the entire transcriptome.
Based on theoretical calculations, 240 pairs of arbitrary and
anchor primers are expected to amplify ,96% of expressed RNA
transcripts [12]. Next-generation transcriptome sequencing (e.g.,
RNA-seq) shares some of these strengths (whole transcriptome
analysis, prior knowledge of transcript sequence not required,
small amounts of starting RNA required), while also offering the
ability to distinguish allelic and splice variants that are not easily
evaluated with differential display [13]. However, RNA-seq
sequencing data will skew towards high abundance transcripts
and the technology remains up to 100-fold more expensive than
differential display [13].
ADE retains the advantages of the differential display technique
while facilitating the analysis of heterogeneous samples. The
pooling of heterogeneous samples efficiently identifies transcripts
that are differentially expressed in a high proportion of the samples
that comprise two groups [10]. We sought to further improve ADE
methodology by accelerating prostate cancer biomarker discovery
in clinically relevant samples. Although the gold standard of
prostate cancer diagnosis is a prostate biopsy, this procedure is
painful, invasive and subject to possible complications of bleeding
and infection. Therefore, biomarkers that can be identified in
samples such as blood are desirable. Since not all tumor-associated
biomarkers will be detectable in blood, starting the discovery
process in tumor tissue will later require the further expenditure of
time and resources for validation in blood samples. In addition,
blood-based biomarkers that represent a host response to tumor
would not be identified if biomarker discovery is initiated in tumor
samples. Special blood collection media allows the efficient
recovery of undegraded RNA from whole blood, even after
prolonged incubation at room temperature, making this a practical
choice for clinical application. We thus decided to start the
biomarker discovery process using whole blood samples.
Although ADE has typically been used to evaluate transcripts
that are differentially expressed in tissue (hence, the terminology
‘‘averaged differential expression’’), we adapted this technique to
identify RNA transcripts that are present at different levels in
whole blood RNA from two groups of patients. These transcripts
are not necessarily differentially expressed in cells that are present
in the blood, or even in tumor compared to normal tissue, but
their presence in the blood can be used to differentiate between
these two groups. In this study, we describe the use of ADE to
identify an RNA transcript, RNF19A (Gene ID: 25897), that is
present at higher levels in the blood of prostate cancer patients
than in healthy controls. These results establish proof-of-principle
that averaged differential expression (ADE) methodology can be
used for the discovery of RNA markers in body fluids of men with
prostate cancer and support the study of RNF19A as a potential
prostate cancer biomarker.
Methods
Ethics Statement
All research involving human participants was approved by the
Henry Ford Health System (HFHS) Institutional Review Board.
Written informed consent was obtained for all participants and all
clinical investigation was conducted according to the principles
expressed in the Declaration of Helsinki.
Patients and Blood Collection
Prostate cancer patients were identified through the Depart-
ment of Urology at the Henry Ford Health System (HFHS).
Healthy controls were recruited from the general population and
HFHS Internal Medicine clinics. Whole blood (2.5 ml) was
collected in PAXgene Blood RNA tubes (Qiagen, Valencia, CA),
allowing for transport at room temperature without RNA
degradation. Samples were frozen at 280uC until extraction of
RNA was performed.
RNA Isolation
Blood in PAXgene Blood RNA tubes was centrifuged. The
pellet was washed with RNase-free water and resuspended in
Trizol reagent (Invitrogen, Carlsbad, CA). RNA was extracted
according to the manufacturer’s protocols. The isolated RNA was
treated with RNase-free DNase (Invitrogen, Carlsbad, CA) and
the concentration of total RNA was determined using a Qubit
Fluorometer (Invitrogen, Carlsbad, CA).
Averaged Differential Expression (ADE)
Total RNA from the blood of 10 patients and 10 healthy men
were pooled separately, reverse transcribed, and subjected to ADE
as described by Bai et al [10]. Anchor and arbitrary primers used
for PCR were H-T11A and H-AP17 (GenHunter Corporation,
Nashville, TN). PCR reactions were carried out in duplicate. PCR
products were electrophoresed and bands detected by autoradi-
ography. Bands that differed in intensity between prostate cancer
patients and healthy men were cut from the gel, re-amplified using
the same anchor and arbitrary primers H-T11A and H-AP17, and
directly sequenced.
qRT-PCR
RNA was reverse transcribed using random hexamer primers
and Transcriptor Reverse Transcriptase (Roche Applied Science,
Indianapolis, IN) according to the manufacturer’s protocol. After
reverse transcription, RNA was subjected to qPCR on an Applied
Biosystems 7500 Fast Real-Time PCR System (Applied Biosys-
tems, Foster City, CA) using sequence-specific primers for
RNF19A (Assay Id: Hs00968447_m1) and 18S RNA (Assay Id:
Hs03928985_g1). The cycle number at which the reaction
crossed a threshold fluorescence (CT) was determined for each
transcript, and the level of each test gene relative to 18S RNA
(reference transcript) was determined using the equation
2
2DC
T where DCT =C T,test –C T,ref [14].
Statistical Methods
Means were compared using a t-test. The equality of the group
variances was tested, and the Satterthwaite p-value was reported
for distributions with unequal variances. The Pearson correlation
coefficient was used to evaluate linear correlation. A receiver
operator curve (ROC) was generated by plotting the sensitivity
against the false positive rate (1 2 specificity) as the discrimination
of the test was varied. Area under the curve (AUC) was calculated.
All statistical computations were done in SAS.
Results and Discussion
Blood samples were obtained from healthy male controls and
men with localized prostate cancer prior to definitive therapy.
After RNA extraction, 20 ng total RNA from each of the 10
prostate cancer patients or from each of the 10 healthy men were
ADE for Prostate Cancer Biomarker Discovery
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healthy) that were then analyzed by ADE as described by Bai et al
[10]. PCR amplification using an anchor and arbitrary primer set
was performed in duplicate and the reaction products were
subjected to gel electrophoresis (Fig. 1).
As shown in Fig. 1, ADE analysis identified two RNA
transcripts amplified at significantly higher levels in blood samples
from prostate cancer patients (Ca) than in those from healthy men
(H). Nucleotide sequence analysis (Fig. S1, supplementary data)
revealed that these two transcripts shared a common sequence and
that this sequence had 100% homology to the nucleotide sequence
in the ring finger protein 19A (RNF19A) mRNA transcript.
RNF19A, also called Dorfin, is an E3 ubiquitin ligase known to be
expressed in the pathologic inclusions found in Parkinson’s disease,
amyotrophic lateral sclerosis, and Lewy body dementia [15].
RNF19A ubiquitinates synphilin-1 and mutated superoxide
dismutase 1 (SOD1), which are implicated in the pathogenesis of
these neurodegenerative disorders [16,17]. RNF19A has not
previously been associated with cancer, which underscores the
utility of differential display in identifying novel associations.
However, both RNF19A and its targets (SOD1 and synphilin-1)
have been implicated in cell survival and cell death pathways
[18,19,20]. SOD1 has been specifically associated with prostate
cancer [21,22] and may be involved in the cellular response to
DNA damage through its role in the oxidative stress pathway.
Other E3-ubiquitin ligases, such as RNF6, are reported to regulate
androgen receptor activity in prostate cancer cells [23].
After the identification of the RNF19A transcript as a potential
biomarker distinguishing the blood of prostate cancer patients
from the blood of healthy controls, qRT-PCR was used to
measure the level of this transcript, relative to that of 18S RNA, in
whole blood RNA samples from individual patients. Relative
RNF19A levels were measured in 33 prostate cancer patients and
19 healthy male controls. These cohorts were independent of the
patient groups used for the ADE discovery process. The control
samples (median age 40 yrs, range 31–50 yrs) were taken from the
general population, and as such, were not age-matched to prostate
cancer cases. Baseline clinical data for the prostate cancer cohort
are shown in Table 1. All prostate cancer cases had conventional
adenocarcinoma on pathologic review and none were documented
to have nodal or distant metastatic disease. Relative RNF19A
levels as measured by qRT-PCR are shown in Fig. 2 (for
comparison of raw CT data, please see supplementary data, Table
S1). The mean relative level of RNF19A was 4.79 6 0.91 (SE) in
prostate cancer patients compared to 1.96 6 0.39 (SE) in healthy
controls. This difference between the two groups was statistically
significant (p=0.0066). A similar statistically significant difference
in RNF19A levels between prostate cancer patients and healthy
controls was obtained when levels were assessed using semi-
quantitative RT-PCR (Fig. S2, supplementary data).
A receiver-operating curve for RNF19A was generated as an
overall estimate of the sensitivity and specificity of this blood
biomarker for distinguishing prostate cancer cases from controls
(Fig. 3). The AUC for the model was 0.7273, where an AUC of 1
corresponds to a diagnostic test with perfect (100%) specificity and
sensitivity. As a point of reference, the AUC for PSA has been
estimated at 0.640–0.678, while the AUC for a popular
nomogram that takes into account other prostate cancer risk
factors in addition to the PSA level has been estimated at 0.691
[24,25,26].
Although this finding is encouraging, it should be noted that
using PSA to differentiate patients with prostate cancer from
controls in our cohorts may have also resulted in an improved
Figure 1. ADE analysis of whole blood RNA from prostate
cancer patients vs. healthy men. ADE analysis identified two RNA
transcripts with levels significantly higher in whole blood RNA from
prostate cancer patients (Ca) than in healthy men (H). Nucleotide
sequence analysis revealed that these two transcripts shared a common
sequence. This sequence had 100% homology to the nucleotide
sequence in the E3-ubiquitin ligase Ring Finger Protein 19a (RNF19A)
transcript and is located in the 39 untranslated region (UTR).
doi:10.1371/journal.pone.0034875.g001
Table 1. Clinical characteristics of the validation prostate
cancer cohort.
Median Range
Age (yrs) 66 53–82
PSA (ng/mL) 6.4 1.3–33.4
Number Percent
Gleason
6 8 24%
71 8 5 5 %
8–10 7 21%
T-stage
cT1a 1 3%
cT1c 30 91%
cT2a 1 3%
cT3a 1 3%
Characteristics of the 33 patients included in the prostate cancer validation
cohort are shown. Age and baseline PSA were abstracted from the time of
diagnosis. Gleason score is as recorded by the clinical genitourinary pathologist.
Clinical staging of the primary tumor is per the 7
th edition of the American Joint
Committee on Cancer (AJCC) staging manual.
doi:10.1371/journal.pone.0034875.t001
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a median age of 40, the expected PSA in our healthy cohort would
be less than 1.0 ng/mL, substantially lower than the median PSA
value of 6.4 ng/mL seen in our prostate cancer cohort. However,
RNF19A levels did not correlate with age (Pearson coefficient of
0.09), making it unlikely that our findings are simply due to an age-
related effect. Clearly, further validation needs to be performed in
populations that more closely resemble the real-world setting of
patients who are being referred for prostate biopsy. In addition, it
remains to be determined whether RNF19A or other such
biomarkers will add additional value to clinically established
methods to establish prostate cancer risk such as PSA, age, race
and family history. This study was not designed to address the
critical question of increased detection of potentially lethal cancer
while avoiding the overdiagnosis of indolent cancer. Further efforts
at biomarker discovery to identify these lethal subtypes are an
essential goal for the future.
In conclusion, we describe here the use of averaged differential
expression to identify RNF19A as an RNA transcript that is
present at significantly higher levels in the blood of prostate cancer
patients compared to healthy controls. In our sample of patients,
this transcript was able to distinguish prostate cancer patients from
controls with an AUC of the receiver-operating curve of 0.7273.
The results discussed here establish proof-of-principle that ADE
methodology can be used for the discovery of RNA markers in the
blood of men with prostate cancer and warrant further analysis of
RNF19A as a clinically relevant biomarker for prostate cancer
early detection.
Supporting Information
Figure S1 Chromatograms of ADE-identified tran-
scripts. Samples from healthy controls and patients with prostate
cancer were subjected to averaged differential expression analysis.
Transcripts (A and B), present at different levels in healthy controls
compared to prostate cancer patients, were submitted for
sequencing. Chromatograms from the sequencing reactions for
both transcript A and B are shown, indicating an identical
common sequence. Given the resolution of the differential display
gel, the difference in length between the two bands (A and B) is no
more than several nucleotides. A different annealing location for
either the random primer or the polyA primer may explain this
result.
(PPT)
Figure S2 RT-PCR analysis of RNF19A in blood from
prostate cancer patients and healthy men. Levels of
RNF19 were evaluated using semi-quantitative RT-PCR. RNA
was reverse transcribed using random hexamers or oligo (dT)
primer and Transcriptor Reverse Transcriptase (Roche Applied
Science) according to the manufacturer’s protocol. Amplification
of cDNA was done using sequence-specific primers of RNF19A
and GAPDH genes. PCR products were run on a 2% agarose gel.
Quantitation of cDNA bands on the gel was carried out by digital
analysis of band intensity using an Eagle Eye II still video system
with the software provided by Stratagene (La Jolla, CA). RNF19A
transcript levels were significantly higher in prostate cancer
patients compared to controls.
(PPT)
Figure 2. RNF19A transcript levels are higher in prostate
cancer patients than in healthy men. Quantitative RT-PCR was
performed on whole blood RNA samples from patients with localized
prostate cancer (n=33) as well as healthy male controls (n=19). Levels
of RNF19A transcript were normalized to 18S RNA (reference gene).
Normalized results are presented in box plot format, with boxes
representing the 25
th,5 0
th, and 75
th percentiles and whiskers represent-
ingthe10
thand90
thpercentilesofthedata. Outliers are also displayed.
The difference between the means was statistically significant (p =
0.0066).
doi:10.1371/journal.pone.0034875.g002
Figure 3. ROC curve evaluating the accuracy of RNF19A as a
diagnostic test. A receiver-operating curve (ROC) was generated as a
preliminary estimate of the accuracy of relative levels of RNF19A in
classifying patients with cancer or healthy controls in our cohort of
patients. The true positive rate (sensitivity) was plotted against the false
positive rate (1-specificity). The area under the curve was calculated as
0.7273.
doi:10.1371/journal.pone.0034875.g003
ADE for Prostate Cancer Biomarker Discovery
PLoS ONE | www.plosone.org 4 April 2012 | Volume 7 | Issue 4 | e34875Table S1 Raw CT data are presented for the validation
cohorts of prostate cancer patients (PrCa pts) and healthy
controls. Mean CT values were lower in PrCa pts compared to
controls (28.25 vs. 29.50, p=0.02). Mean CT values for the 18S
reference gene were not statistically different between patients
and controls (16.62 vs 16.67, p=0.89). Means were compared
using a t-test.
(DOC)
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